Presented by:
Kent Mathias, MD
Assistant Professor, Department of Psychiatry & Addiction Medicine
Faculty Disclosure:
Dr. Mathias has disclosed that he has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.
Release Date: September 29, 2023
Expiration Date: September 28, 2025
Target Audience: All physicians
Learning Objectives:
As a result of participation in this activity, participants should be able to:
- Define designer drugs.
- Recognize new designer drugs and detox considerations.
- Cite terminology related to street and designer drugs.
- Describe trends in designer drugs.
Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.
Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Resources for further study:
- https://www.8newsnow.com/wp-content/uploads/sites/59/2021/09/fentanyl-lethal-dose.jpg?resize=876,492
- https://cdn.britannica.com/
- https://www.dea.gov/sites/default/files/drug_fact_sheets
- https://d3i71xaburhd42.cloudfront.net/28c6b192fa21b7a4d0e17f127f29460c83272ec9/250px/7-Figure2-1.png
- DEA Washington, DC Division – Public Information Office. (2022, June 1). New, Dangerous Synthetic Opioid in D.C., Emerging in Tri-State Area. Drug Enforcement Administration. https://www.dea.gov/stories/2022/2022-06/2022-06-01/new-dangerous-synthetic-opioid-dc-emerging-tri-state-area
- Mérette, S. A. M., Thériault, S., Piramide, L. E. C., Davis, M. D., & Shapiro, A. M. (2023). Bromazolam Blood Concentrations in Postmortem Cases-A British Columbia Perspective. Journal of Analytical Toxicology, 47(4), 385-392. https://doi.org/10.1093/jat/bkad005
- Niello, M., Sideromenos, S., Gradisch, R., O’Shea, R., Schwazer, J., Maier, J., Kastner, N., Sandtner, W., Jäntsch, K., Lupica, C. R., Hoffman, A. F., Lubec, G., Loland, C. J., Stockner, T., Pollak, D. D., Baumann, M. H., & Sitte, H. H. (2023). Persistent binding at dopamine transporters determines sustained psychostimulant effects. Proceedings of the National Academy of Sciences of the United States of America, 120(6), e2114204120. https://doi.org/10.1073/pnas.2114204120
- Humphreys, K., Shover, C. L., Andrews, C. M., Bohnert, A. S. B., Brandeau, M. L., Caulkins, J. P., Chen, J. H., Cuéllar, M.-F., Hurd, Y. L., Juurlink, D. N., Koh, H. K., Krebs, E. E., Lembke, A., Mackey, S. C., Ouellette, L. L., Suffoletto, B., & Timko, C. (2022). Responding to the opioid crisis in North America and beyond: recommendations of the Stanford–Lancet Commission. The Lancet, 399(10324). https://www.thelancet.com/commissions/opioid-crisis
- Centers for Disease Control and Prevention (CDC). (2021). Drug overdose deaths in the United States by drug category. U.S. Department of Health & Human Services. https://www.nist.gov/feature-stories/safe-efficient-reliable-new-science-fight-against-killer-drugs
- Substance Abuse and Mental Health Services Administration. (2020). 2020 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions. U.S. Department of Health & Human Services. https://www.samhsa.gov/data/sites/default/files/reports/rpt35330/2020NSDUHMethodSummDefs091721.pdf
- Hardman, M. I., Sprung, J., & Weingarten, T. N. (2019). Acute phenibut withdrawal: A comprehensive literature review and illustrative case report. Bosnian Journal of Basic Medical Sciences, 19(2), 125-129. https://doi.org/10.17305/bjbms.2018.4008
- Brunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busardò FP. Designer Benzodiazepines: A Review of Toxicology and Public Health Risks. Pharmaceuticals (Basel). 2021 Jun 11;14(6):560. doi: 10.3390/ph14060560. PMID: 34208284; PMCID: PMC8230725.
- Florida Medical Examiners Commission & Florida Department of Law Enforcement. (2023, July). Drugs identified in deceased persons: 2022 Interim Report. https://www.fdle.state.fl.us/MEC/Publications-and-Forms/Documents/Drugs-in-Deceased-Persons/2022-Interim-Drug-Report-FINAL.aspx
If you have any questions please feel free to contact Nancy Boyd at (352) 594-4298 or at nancy.boyd@ufl.edu
Section #: 2579